Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: Reuters Investment Profile
$20.00
Provider: BuySellSignals Research
$5.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

EU, UK evaluating FDA findings on Ranbaxy Laboratories Ltd's Toansa facility-businesstoday


Wednesday, 29 Jan 2014 01:30pm EST 

Ranbaxy Laboratories Ltd:US FDA banned import of Ranbaxy products to America from Toansa plant , health regulators of EU and the UK have said they are evaluating the FDA inspection findings to assess if deviations from Good Manufacturing Practice (GMP) have any implication in their markets- businesstoday.European Medicines Agency (EMA), said Ranbaxy Laboratories site in Toansa, Punjab is a supplier of active ingredients for four centrally authorised medicines Enyglid, Repaglinide Krka, Repaglinide Teva and Nevirapine Teva, besides several non-centrally authorised medicines.As part of this evaluation, the EMA and national medicines authorities will take 'any measures necessary to protect' the health of EU patients should a risk to public health be identified.Citing manufacturing norm violations, the FDA had last week prohibited Ranbaxy Laboratories from distributing drugs produced at the Toansa unit in the US, including medicines made by the company's Ohm Laboratories facility in New Jersey.The Medicines and Healthcare Products Regulatory Agency (MHRA) of UK said they are aware of the results of the FDAs inspection relating to GMP issues at the Toansa plant.MHRA said as of now, they found no evidence that Ranbaxy's medicines in the UK are defective, so people can continue to consumes them as usual.